Skip to main content
Top
Published in: Tumor Biology 3/2016

Open Access 01-03-2016 | Original Article

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient

Authors: Giuliana Cavalloni, Caterina Peraldo-Neia, Chiara Varamo, Laura Casorzo, Carmine Dell’Aglio, Paola Bernabei, Giovanna Chiorino, Massimo Aglietta, Francesco Leone

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Biliary tract carcinoma is a rare malignancy with multiple causes, which underlie the different genetic and molecular profiles. Cancer cell lines are affordable models, reflecting the characteristics of the tumor of origin. They represent useful tools to identify molecular targets for treatment. Here, we established and characterized from biological, molecular, and genetic point of view, an Italian intrahepatic cholangiocarcinoma cell line (ICC), the MT-CHC01. MT-CHC01 cells were isolated from a tumor-derived xenograft. Immunophenotypical characterization was evaluated both at early and after stabilization passages. In vitro biological, genetic, and molecular features were also investigated. In vivo tumorigenicity was assessed in NOD/SCID mice. MT-CHC01cells retain epithelial cell markers, EPCAM, CK7, and CK19, and some stemness and pluripotency markers, i.e., SOX2, Nanog, CD49f/integrin-α6, CD24, PDX1, FOXA2, and CD133. They grow as a monolayer, with a population double time of about 40 h; they show a low migration and invasion potential. In low attachment conditions, they are able to form spheres and to growth in anchorage-independent manner. After subcutaneous injection, they retain in vivo tumorigenicity; the expression of biliary markers as CA19-9 and CEA were maintained from primary tumor. The karyotype is highly complex, with a hypotriploid to hypertriploid modal number (3n+/−) (52 to 77 chromosomes); low level of HER2 gene amplification, TP53 deletion, gain of AURKA were identified; K-RAS G12D mutation were maintained from primary tumor to MT-CHC01 cells. We established the first ICC cell line derived from an Italian patient. It will help to study either the biology of this tumor or to test drugs both in vitro and in vivo.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.CrossRefPubMed Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.CrossRefPubMed
2.
go back to reference Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.CrossRefPubMed Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.CrossRefPubMed
4.
go back to reference Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 2010;101:579–85.CrossRefPubMed Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 2010;101:579–85.CrossRefPubMed
5.
go back to reference Poomphakwaen K, Promthet S, Kamsa-Ard S, Vatanasapt P, Chaveepojnkamjorn W, Klaewkla J, et al. Risk factors for cholangiocarcinoma in khon kaen, thailand: a nested case–control study. Asian Pac J Cancer Prev. 2009;10:251–8.PubMed Poomphakwaen K, Promthet S, Kamsa-Ard S, Vatanasapt P, Chaveepojnkamjorn W, Klaewkla J, et al. Risk factors for cholangiocarcinoma in khon kaen, thailand: a nested case–control study. Asian Pac J Cancer Prev. 2009;10:251–8.PubMed
6.
go back to reference Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.CrossRefPubMed Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.CrossRefPubMed
7.
go back to reference Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in japan. Br J Cancer. 2010;103:469–74.CrossRefPubMedPubMedCentral Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in japan. Br J Cancer. 2010;103:469–74.CrossRefPubMedPubMedCentral
9.
go back to reference Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64.CrossRefPubMed Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64.CrossRefPubMed
10.
go back to reference Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.CrossRefPubMedPubMedCentral Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.CrossRefPubMedPubMedCentral
11.
go back to reference Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis c virus-related cirrhosis. Cancer. 2000;88:2471–7.CrossRefPubMed Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis c virus-related cirrhosis. Cancer. 2000;88:2471–7.CrossRefPubMed
12.
go back to reference Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the united states: a case–control study. Gastroenterology. 2005;128:620–6.CrossRefPubMed Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the united states: a case–control study. Gastroenterology. 2005;128:620–6.CrossRefPubMed
13.
go back to reference Ma S, Hu L, Huang XH, Cao LQ, Chan KW, Wang Q, et al. Establishment and characterization of a human cholangiocarcinoma cell line. Oncol Rep. 2007;18:1195–200.PubMed Ma S, Hu L, Huang XH, Cao LQ, Chan KW, Wang Q, et al. Establishment and characterization of a human cholangiocarcinoma cell line. Oncol Rep. 2007;18:1195–200.PubMed
14.
go back to reference Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (kku-100). World J Gastroenterol. 2005;11:3392–7.CrossRefPubMedPubMedCentral Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (kku-100). World J Gastroenterol. 2005;11:3392–7.CrossRefPubMedPubMedCentral
15.
go back to reference Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002;87:187–93.CrossRefPubMedPubMedCentral Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002;87:187–93.CrossRefPubMedPubMedCentral
16.
go back to reference Katoh H, Shinbo T, Otagiri H, Saitoh M, Saitoh T, Ishizawa S, et al. [character of a human cholangiocarcinoma chgs, serially transplanted to nude mice]. Hum Cell. 1988;1:101–5.PubMed Katoh H, Shinbo T, Otagiri H, Saitoh M, Saitoh T, Ishizawa S, et al. [character of a human cholangiocarcinoma chgs, serially transplanted to nude mice]. Hum Cell. 1988;1:101–5.PubMed
17.
go back to reference Jiao W, Yakushiji H, Kitajima Y, Ogawa A, Miyazaki K. Establishment and characterization of human hilar bile duct carcinoma cell line and cell strain. J Hepatobiliary Pancreat Surg. 2000;7:417–25.CrossRefPubMed Jiao W, Yakushiji H, Kitajima Y, Ogawa A, Miyazaki K. Establishment and characterization of human hilar bile duct carcinoma cell line and cell strain. J Hepatobiliary Pancreat Surg. 2000;7:417–25.CrossRefPubMed
18.
go back to reference Yamada N, Chung YS, Arimoto Y, Sawada T, Seki S, Sowa M. Establishment of a new human extrahepatic bile duct carcinoma cell line (ocuch-lm1) and experimental liver metastatic model. Br J Cancer. 1995;71:543–8.CrossRefPubMedPubMedCentral Yamada N, Chung YS, Arimoto Y, Sawada T, Seki S, Sowa M. Establishment of a new human extrahepatic bile duct carcinoma cell line (ocuch-lm1) and experimental liver metastatic model. Br J Cancer. 1995;71:543–8.CrossRefPubMedPubMedCentral
19.
go back to reference Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, tfk-1. Tohoku J Exp Med. 1995;177:61–71.CrossRefPubMed Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, tfk-1. Tohoku J Exp Med. 1995;177:61–71.CrossRefPubMed
20.
go back to reference Yoshida K, Tomizawa H, Ota T, Nagashima T, Kikuchi H, Watanabe H, et al. [Establishment and characterization of human cholaginocarcinoma, MEC, producing carbohydrate antigen 19–9]. Hum Cell. 1990;3:346–51.PubMed Yoshida K, Tomizawa H, Ota T, Nagashima T, Kikuchi H, Watanabe H, et al. [Establishment and characterization of human cholaginocarcinoma, MEC, producing carbohydrate antigen 19–9]. Hum Cell. 1990;3:346–51.PubMed
21.
go back to reference Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl). 1988;188:367–75.CrossRef Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl). 1988;188:367–75.CrossRef
22.
go back to reference Ghosh M, Koike N, Tsunoda S, Hirano T, Kaul S, Kashiwagi H, et al. Characterization and genetic analysis in the newly established human bile duct cancer cell lines. Int J Oncol. 2005;26:449–56.PubMed Ghosh M, Koike N, Tsunoda S, Hirano T, Kaul S, Kashiwagi H, et al. Characterization and genetic analysis in the newly established human bile duct cancer cell lines. Int J Oncol. 2005;26:449–56.PubMed
23.
go back to reference Takiyama I, Terashima M, Ikeda K, Kawamura H, Kashiwaba M, Tamura G, et al. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (ICBD-1). Oncol Rep. 1998;5:463–7.PubMed Takiyama I, Terashima M, Ikeda K, Kawamura H, Kashiwaba M, Tamura G, et al. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (ICBD-1). Oncol Rep. 1998;5:463–7.PubMed
24.
go back to reference Yano H, Maruiwa M, Iemura A, Mizoguchi A, Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer. 1992;69:1664–73.CrossRefPubMed Yano H, Maruiwa M, Iemura A, Mizoguchi A, Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer. 1992;69:1664–73.CrossRefPubMed
25.
go back to reference Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma characterisation of three new human tumor cell lines. J Hepatol. 1985;1:579–96.CrossRefPubMed Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma characterisation of three new human tumor cell lines. J Hepatol. 1985;1:579–96.CrossRefPubMed
26.
go back to reference Kim DG, Park SY, You KR, Lee GB, Kim H, Moon WS, et al. Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosom Cancer. 2001;30:48–56.CrossRefPubMed Kim DG, Park SY, You KR, Lee GB, Kim H, Moon WS, et al. Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosom Cancer. 2001;30:48–56.CrossRefPubMed
27.
go back to reference Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S, Pausawasdi A. Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol. 1991;9:153–7.PubMed Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S, Pausawasdi A. Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol. 1991;9:153–7.PubMed
28.
go back to reference Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst. 1985;75:29–35.PubMed Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst. 1985;75:29–35.PubMed
29.
go back to reference Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-t1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol. 1989;25:503–10.CrossRefPubMed Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-t1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol. 1989;25:503–10.CrossRefPubMed
30.
go back to reference Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosom Cancer. 1990;2:300–10.CrossRefPubMed Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosom Cancer. 1990;2:300–10.CrossRefPubMed
31.
go back to reference Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992;52:252–60.CrossRefPubMed Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992;52:252–60.CrossRefPubMed
32.
go back to reference Iemura A, Maruiwa M, Yano H, Kojiro M. A new human cholangiocellular carcinoma cell line (KMC-1). J Hepatol. 1992;15:288–98.CrossRefPubMed Iemura A, Maruiwa M, Yano H, Kojiro M. A new human cholangiocellular carcinoma cell line (KMC-1). J Hepatol. 1992;15:288–98.CrossRefPubMed
33.
go back to reference Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, et al. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer. 2014;14:918.CrossRefPubMedPubMedCentral Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, et al. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer. 2014;14:918.CrossRefPubMedPubMedCentral
34.
go back to reference Shaffer LG, Mc Gowan-Jordan J, Shmid M: Iscn. An international system for human cytogenetic nomenclature. Basel, Swizterland, Karger Medical and Scientific Publishers, 2013 Shaffer LG, Mc Gowan-Jordan J, Shmid M: Iscn. An international system for human cytogenetic nomenclature. Basel, Swizterland, Karger Medical and Scientific Publishers, 2013
35.
go back to reference Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.CrossRefPubMed Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.CrossRefPubMed
36.
go back to reference Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.CrossRefPubMedPubMedCentral Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.CrossRefPubMedPubMedCentral
37.
go back to reference Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54:2159–72.CrossRefPubMed Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54:2159–72.CrossRefPubMed
38.
go back to reference Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, et al. Antitumor activity of src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012;11:1528–38.CrossRefPubMed Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, et al. Antitumor activity of src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012;11:1528–38.CrossRefPubMed
39.
40.
go back to reference Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490–5.CrossRefPubMed Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490–5.CrossRefPubMed
41.
go back to reference Rowehl RA, Burke S, Bialkowska AB, Pettet DW, Rowehl L, Li E, et al. Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells. PLoS One. 2014;9, e99091.CrossRefPubMedPubMedCentral Rowehl RA, Burke S, Bialkowska AB, Pettet DW, Rowehl L, Li E, et al. Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells. PLoS One. 2014;9, e99091.CrossRefPubMedPubMedCentral
42.
go back to reference Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.CrossRefPubMed Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.CrossRefPubMed
44.
go back to reference Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767–75.CrossRefPubMed Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767–75.CrossRefPubMed
45.
go back to reference Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001;130:22–8.CrossRefPubMed Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001;130:22–8.CrossRefPubMed
46.
go back to reference Uhm KO, Park YN, Lee JY, Yoon DS, Park SH. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2005;157:37–41.CrossRefPubMed Uhm KO, Park YN, Lee JY, Yoon DS, Park SH. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2005;157:37–41.CrossRefPubMed
47.
go back to reference Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, Kern SE, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosom Cancer. 1999;26:185–91.CrossRefPubMed Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, Kern SE, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosom Cancer. 1999;26:185–91.CrossRefPubMed
Metadata
Title
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
Authors
Giuliana Cavalloni
Caterina Peraldo-Neia
Chiara Varamo
Laura Casorzo
Carmine Dell’Aglio
Paola Bernabei
Giovanna Chiorino
Massimo Aglietta
Francesco Leone
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4215-3

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine